Aethlon Medical, Inc. (AEMD) Stock Score, Valuation & Financial Research

Aethlon Medical, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AEMD

Aethlon Medical, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.09. These figures are a research snapshot, not a buy or sell recommendation.

What Aethlon Medical, Inc. does

Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Aethlon Medical is a clinical-stage medical therapeutic company that does not currently generate revenue from product sales. Its business model is focused on the research and development of the Hemopurifier, an investigational device designed to remove viruses and tumor-derived extracellular vesicles from the circulatory system, with the goal of eventually commercializing these therapies for cancer and infectious diseases.

Products and services

  • The Hemopurifier is an investigational immunotherapeutic device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation to treat cancer and life-threatening viral infections.

Brands and product families

  • Hemopurifier — The company's primary investigational immunotherapeutic device. Source

Customer types

Clinical research institutions and hospitals.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its investigational devices; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Companies developing infectious disease and cancer treatment procedures — The company operates in an extremely competitive industry where various entities develop new treatment procedures for infectious diseases and cancer. Source

Business strengths to evaluate

  • Proprietary Hemopurifier technology platform Source

Business risks and research considerations

  • History of operating losses and dependence on additional capital Source
  • Regulatory and clinical trial uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AEMD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.09
Market capitalization:
3.21M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -6.94M
Free cash flow:
USD -7M
Cash:
USD 4.93M
Total debt:
USD 367.61K
EPS:
USD -11.70

What stands out

  • Free cash flow is USD -7M, negative for the stored period.
  • The balance sheet shows USD 4.93M of cash versus USD 367.61K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AEMD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AEMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AEMD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AEMD to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of AEMD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AEMD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.